Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Biobank For MS And Other Demyelinating Diseases

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Accelerated Cure Project for Multiple Sclerosis
ClinicalTrials.gov Identifier:
NCT00445367
First received: March 8, 2007
Last updated: March 5, 2013
Last verified: March 2013
  Purpose

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.


Condition
Multiple Sclerosis
Transverse Myelitis
Neuromyelitis Optica
Acute Disseminated Encephalomyelitis
Optic Neuritis

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Large-scale, Multi-disciplinary Sample and Data Repository for Multiple Sclerosis and Related Demyelinating Diseases

Resource links provided by NLM:


Further study details as provided by Accelerated Cure Project for Multiple Sclerosis:

Study Start Date: May 2006
Groups/Cohorts
Case
Control

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.

Criteria

Inclusion Criteria:

  • age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
  • willing to provide up to 110 ml (50 ml for < 18 years old) of blood via venipuncture
  • experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON

Exclusion Criteria:

  • history of blood borne pathogens
  • allogeneic bone marrow transplant
  • clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
  • weight less than 37 pounds
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00445367

Locations
United States, Arizona
Barrow Neurological Institute
Phoenix, Arizona, United States, 85013
United States, California
Stanford University
Stanford, California, United States, 94305
United States, Colorado
The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
Aurora, Colorado, United States, 80045
United States, Georgia
Shepherd Center
Atlanta, Georgia, United States, 30309
United States, Maryland
Johns Hopkins
Baltimore, Maryland, United States, 21287
United States, Massachusetts
Beth Israel Deaconess
Boston, Massachusetts, United States, 02215
University of Massachusetts Medical School
Worcester, Massachusetts, United States, 01605
United States, New York
Multiple Sclerosis Research Center of New York
New York, New York, United States, 10019
United States, Ohio
The Ohio State University
Columbus, Ohio, United States, 43210
United States, Texas
University of Texas Southwestern Medical Center at Dallas
Dallas, Texas, United States, 76051
Sponsors and Collaborators
Accelerated Cure Project for Multiple Sclerosis
Investigators
Principal Investigator: Benjamin Greenberg, M.D., M.H.S. University of Texas
  More Information

Additional Information:
No publications provided

ClinicalTrials.gov Identifier: NCT00445367     History of Changes
Other Study ID Numbers: ACP-001
Study First Received: March 8, 2007
Last Updated: March 5, 2013
Health Authority: United States: Institutional Review Board

Keywords provided by Accelerated Cure Project for Multiple Sclerosis:
Multiple Sclerosis
Clinically Isolated Syndrome
Transverse Myelitis
Neuromyelitis Optica
Acute Disseminated Encephalomyelitis
Optic Neuritis
Repository
Biobank

Additional relevant MeSH terms:
Demyelinating Diseases
Encephalomyelitis
Encephalomyelitis, Acute Disseminated
Multiple Sclerosis
Myelitis
Myelitis, Transverse
Neuritis
Neuromyelitis Optica
Optic Neuritis
Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Brain Diseases
Central Nervous System Diseases
Central Nervous System Infections
Central Nervous System Viral Diseases
Cranial Nerve Diseases
Demyelinating Autoimmune Diseases, CNS
Encephalitis
Eye Diseases
Immune System Diseases
Leukoencephalopathies
Neoplasms
Neoplasms by Site
Nervous System Diseases
Nervous System Neoplasms
Neurodegenerative Diseases
Neuromuscular Diseases
Optic Nerve Diseases
Paraneoplastic Syndromes

ClinicalTrials.gov processed this record on November 25, 2014